Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)

Inclusion criteria

• Pathological histology and/or cytology confirmed NSCLC;
• Based on AJCC Cancer Staging, IIIA, IIIB, IV lung cancer patients with NSCLC;
• PS 0-2;
• Expected survival > 3 months;
• Age 18~75 years old;
• The function of lung, liver, kidney, bone marrow was normal;
• The patients had not received radiotherapy for previous primary tumor and metastases;
• At least accept 2-4 cycles of chemotherapy,not disease progression after chemotherapy,start radiotherapy in two weeks after the last cycle of chemotherapy;
• Wild-type EGFR;
• Sensitive mutant EGFR, but refused to targeted therapy;
• In line with the indications of radiotherapy and accept it;
• Voluntarily enrolled to participate in,better compliance, cooperate with experimental observations, and sign informed consent.

Exclusion criteria

• Vital organs (e.g., heart, liver, kidney) have serious dysfunction;
• Patients with other malignancies;
• Patients with a history of autoimmune disease;
• The patients are pregnant and lactating (Women of childbearing age need to check the pregnancy test);
• In the activity of acute or chronic infectious diseases;
• Patients with a clear history of drug allergy or allergic genus;
• Patients with participating in other clinical trials at the same time;
• Other cases that researchers believe that patients should not participate in the present trial.